Target intelligence / Profile preview

DLG3 antisense RNA 1 (DLG3-AS1)

Target
DLG3-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA
01

Overview

DLG3 antisense RNA 1 (DLG3-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the DLG3 gene locus. As an antisense RNA, it does not encode a protein but may regulate the expression, splicing, and stability of its sense counterpart (DLG3) or participate in broader chromatin or epigenetic regulatory mechanisms. Antisense lncRNAs like DLG3-AS1 have been implicated in the regulation of gene expression at transcriptional and post-transcriptional levels; in some contexts, antisense lncRNAs modulate cell proliferation, differentiation, or tumorigenesis, although no direct evidence is available for DLG3-AS1 specifically[1][2][3]. Currently, DLG3-AS1 is not recognized as a direct therapeutic target, biomarker, or druggable entity. Key points: - DLG3-AS1 is classified as a non-coding, antisense lncRNA, not as a receptor, enzyme, or classical therapeutic target[1][2][3]. - There are no known drugs that interact with DLG3-AS1, and mechanisms of action for therapeutics targeting DLG3-AS1 are not reported. - DLG3-AS1’s functions and disease associations remain largely uncharacterized beyond general roles established for long non-coding antisense RNAs[3].

Other names
DLG3-AS1DLG3 antisense RNA 1 (non-protein coding)
02

Biological functions

Regulation of gene expressionEpigenetic modulationPost-transcriptional regulation of mRNAsPotential involvement in cell proliferation and cancer-related processes
03

Disease associations

Cancer (general evidence for antisense lncRNAs, but specific disease associations for DLG3-AS1 are not clearly characterized)

Beyond the preview

Go deeper on DLG3 antisense RNA 1 (DLG3-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DLG3 antisense RNA 1 (DLG3-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call